FUKOKU MUTUAL LIFE INSURANCE Co cut its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,280 shares of the company's stock after selling 200 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co's holdings in Johnson & Johnson were worth $2,346,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Bank of Hawaii lifted its position in Johnson & Johnson by 0.6% during the fourth quarter. Bank of Hawaii now owns 63,274 shares of the company's stock worth $11,177,000 after purchasing an additional 405 shares during the period. Guyasuta Investment Advisors Inc. lifted its position in Johnson & Johnson by 0.4% during the fourth quarter. Guyasuta Investment Advisors Inc. now owns 264,372 shares of the company's stock worth $46,701,000 after purchasing an additional 987 shares during the period. New York State Common Retirement Fund lifted its position in Johnson & Johnson by 1.1% during the fourth quarter. New York State Common Retirement Fund now owns 4,903,076 shares of the company's stock worth $866,128,000 after purchasing an additional 53,258 shares during the period. Armor Investment Advisors LLC lifted its position in Johnson & Johnson by 8.0% during the fourth quarter. Armor Investment Advisors LLC now owns 14,318 shares of the company's stock worth $2,529,000 after purchasing an additional 1,060 shares during the period. Finally, Curated Wealth Partners LLC lifted its position in Johnson & Johnson by 7.6% during the fourth quarter. Curated Wealth Partners LLC now owns 1,542 shares of the company's stock worth $272,000 after purchasing an additional 109 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Get Johnson & Johnson alerts:Analysts Set New Price Targets
Several equities research analysts recently weighed in on JNJ shares. Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a "neutral" rating and a $161.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a "strong-buy" rating for the company. Raymond James dropped their target price on shares of Johnson & Johnson from $185.00 to $181.00 in a report on Wednesday. Finally, Atlantic Securities increased their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a "neutral" rating in a report on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $173.07.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the firm's stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company's stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company's stock.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $162.53 on Thursday. The company has a market capitalization of $423.27 billion, a PE ratio of 24.11, a P/E/G ratio of 2.86 and a beta of 0.53. The company has a 50 day simple moving average of $157.43 and a two-hundred day simple moving average of $166.99. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts' consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.67 EPS. Research analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.13. Johnson & Johnson's dividend payout ratio is currently 67.06%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.